Navigation Links
DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Date:10/24/2011

TORONTO, Oct. 24, 2011 /PRNewswire/ -- DLVR Therapeutics Inc. ("DLVR") - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle -announced today that the Company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support.  MaRS Innovation joins the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in the company.  The additional funds will be used by DLVR to advance its small molecule chemotherapeutic program towards a pre-clinical regulatory package and continue development of its small interfering RNA (siRNA) program.

"This additional financing highlights the significant potential of our nanoparticle delivery platform approach," stated Mr. Frank Gleeson, President and CEO of DLVR. "Our nanoparticles offer a unique and selective delivery of the payload to the cytosol of the intended target reducing undesired side effects.  MaRS Innovation has recognized this great potential and its investment enables us to accelerate our efforts to advance a chemotherapeutic candidate into IND-enabling studies."

The company's initial development strategy is focused on exploiting the natural targeting approach of DLVR's technology to cancer cells.  With proof-of-concept studies completed, the company is well on its way to identifying a clinical candidate while securing partnerships to further develop delivery of siRNA payloads.  Co-incident with the transaction, Raphael (Rafi) Hofstein, PhD, President and CEO of MaRS Innovation, will join DLVR's board of directors and Parimal Nathwani, Vice-President of MaRS Innovation will become a member of the company's management team in a business development capacity.

"We are very pleased to be joining UHN and OICR in supporting this new and exciting company," stated Dr. Hofstein.  "DLVR provides a unique technology platform that addresses critical and unmet clinical needs in the delivery of chemotherapeutics and RNA interference-based therapeutics.  Our investment highlights the collaborative nature that MaRS Innovation has with its member institutions in helping create and advance Canadian technology."

About DLVR Therapeutics Inc.

DLVR Therapeutics Inc. is a privately-held biotechnology company established in Toronto, Ontario based on the technology developed by Dr. Gang Zheng of UHN.  Co-founded in 2011 by UHN, OICR and MaRS Innovation, the company is focused on developing a novel, HDL-like Peptide-Phospholipid Scaffold nanoparticle delivery system that selectively targets lipophilic small molecules and siRNA to cancer cells.  The company has two principal programs: the first is focused on improving the safety and/or efficacy of known chemotherapeutic drugs; the second is focused on the targeted delivery of siRNA.  DLVR is actively seeking partners to enter into drug development collaborations with biopharmaceutical companies for both programs. For more information visit www.dlvrtherapeutics.ca

About MaRS Innovation

MaRS Innovation provides an integrated commercialization platform that harnesses the economic potential of the exception discovery pipeline of 16 leading academic institutions in Ontario.  MaRS Innovation is a not-for-profit organization with an independent industry-led board of directors, funded through the Government of Canada's Networks of Centres of Excellence, the Province of Ontario through the Ministry of Research and Innovation, and contributions of its member institutions.  Designed to enhance the commercial output of Toronto's outstanding scientific research cluster, MaRS Innovation will make a significant contribution to Canada's economic outlook and the quality of life for Canadians and others around the world.  MaRS Innovation will advance commercialization through industry partnerships, licensing and company creation.  The MaRS Innovation mission is to put Canada on the global innovation stage, by better connection of research with industry and strengthening Canada's competitive capacity in the knowledge based business. – in short, to launch a new generation of robust high growth Canadian companies that will become global market leaders.  For more information, visit www.marsinnovation.com


'/>"/>
SOURCE DLVR Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
2. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
3. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
4. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
5. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
6. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
7. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
8. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
9. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
10. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
11. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)...   Invitae Corporation (NYSE: NVTA), one ... announced the availability of a new genetic test ... (SMA) , a neuromuscular disease that is one ... as well as a significant cause of progressive ... during the American College of Medical Genetics (ACMG) ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... endogenous hormones to regulate homeostasis via their cognate nuclear receptors. By either ... reproductive, neurological, proliferative, and immunological disorders. EDC exposure can occur directly, through ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... disorders, today announced that it has entered into an exclusive global license agreement ... bowel disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease ...
(Date:3/20/2017)... ... March 20, 2017 , ... Charm Sciences, Inc. is ... system that counts Peel Plate microbial test colonies, stores plate images, exports and ... has an internal computer, and is accurate within 10% of an experienced microbiologist’s ...
Breaking Biology Technology:
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/27/2017)... Strategic Cyber Ventures , the industry,s first cybersecurity focused ... investment in  Polarity , the first commercial human memory-augmentation ... and is led by cybersecurity veterans Tom Kellermann ... , also a longtime cybersecurity veteran and founder of ... round of funding. This new funding will be used ...
Breaking Biology News(10 mins):